Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide does cause a modest, measurable rise in resting heart rate for many people — typically around two to three beats per minute on average, though some individuals notice more. This is a real pharmacological effect, not a sign something has gone wrong, and for most people it settles or becomes unnoticeable within the first few weeks. It is worth understanding what is happening and when the effect deserves medical attention, because these are not quite the same question. Wegovy and other semaglutide-containing medicines are prescription-only, and how this effect plays out in any individual depends on their existing health picture — something a prescriber reviews before treatment starts and monitors throughout.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When people notice their pulse is a little quicker than usual after starting Wegovy, the natural assumption is that something has gone wrong. That concern is understandable, but the evidence tells a more nuanced story. The small heart-rate rise seen with semaglutide is a known, studied effect, not an unexpected alarm signal, and our page on how semaglutide interacts with heart rate explores the underlying mechanisms in detail. In the STEP 1 trial, published in the New England Journal of Medicine, participants on 2.4mg semaglutide saw average resting heart rates increase by around two to three beats per minute compared with placebo. That is a statistically visible change, but it sits comfortably within everyday normal variation for most adults.
The reason this happens comes down to how GLP-1 receptor agonists work. GLP-1 receptors are not confined to the gut and pancreas, they are also expressed in the sinoatrial node, the heart's natural pacemaker. Activating those receptors has a mild chronotropic effect, meaning it tends to increase firing rate. The body does not experience this as stress; it is more analogous to the gentle elevation you might see after a cup of coffee. Context matters a great deal here. Someone whose resting heart rate sits at 58 bpm reaching 62 bpm is a different situation from someone already at 90 bpm who climbs higher. A prescriber reviews your baseline before treatment begins for exactly this reason.
So the myth to correct is not that semaglutide never raises heart rate, it does. The myth is that a raised heart rate is automatically a danger sign. For most people, it is neither clinically significant nor something that alters the risk-benefit calculation.
A question our prescribers hear most weeks goes something like: "My smartwatch says my heart rate has gone up by ten beats, should I stop the injection?" If you have found yourself asking whether semaglutide is making your heart race, the short answer is: do not stop without speaking to your prescriber first, but do report it. A rise of two to five beats is within the expected range. A sustained jump of ten beats or more at rest, or palpitations that feel uncomfortable, fluttery, or are accompanied by dizziness, chest tightness, or breathlessness, are worth discussing promptly with your GP or prescriber.
It is also worth knowing that the relationship between semaglutide and cardiovascular outcomes in broader terms is actively researched. The NHS medicines information for semaglutide notes that the medicine has been studied in people with established cardiovascular disease, where it showed a reduction in major cardiac events rather than harm, a finding that shapes how prescribers weigh the modest heart-rate increase against overall benefit. That context does not mean individual symptoms should be dismissed; it means the picture is more reassuring than the single data point of a faster pulse might suggest.
People with a history of arrhythmia, significant valve disease, or other cardiac conditions should discuss this specifically at consultation. These are not automatic contraindications, but they do require a more careful clinical conversation. If you want to explore how the broader cardiovascular picture relates to semaglutide, our page on how semaglutide affects the heart covers that in more depth.
Most people who notice a heart-rate change on Wegovy do so in the early weeks of treatment or after a dose increase. There are a few practical things that help distinguish a normal adjustment from something that warrants a call to your prescriber.
First, hydration. Nausea and reduced appetite can mean people drink less, which in turn can raise the resting pulse independently of semaglutide. Staying well hydrated (particularly through any early GI side effects) removes one confounding factor. Second, caffeine and stimulants. These have their own modest chronotropic effect, and combining them with the early weeks of semaglutide can make the perceived change feel more pronounced. Third, timing. Our page on Wegovy and heart rate recommends checking your heart rate at the same time each morning, before you get up, as this gives you a more reliable baseline than a reading taken mid-afternoon after a walk. If you use a wearable, look at trends over a week rather than reacting to individual readings.
If you are considering the cost side of treatment and whether private prescription is the right route, our guide to Wegovy pricing in the UK sets out what a legitimate prescription service includes and what to look for. For anyone thinking about starting treatment or reviewing their current dose, the right conversation is with a prescriber who can look at your full health history, not a forum or a tracker app.
Our Wegovy treatment page gives a fuller overview of how the medicine works and what the consultation process involves. If you have a specific concern about heart symptoms you are already experiencing, speak to your GP in the first instance, or contact our clinical team through the aftercare support page.
Semaglutide does raise heart rate modestly in most people. It is a direct pharmacological effect, it is documented in trial data, and it is factored into how the medicine is prescribed. For the overwhelming majority of people using Wegovy for weight management, the rise is small, transient, and clinically unremarkable. What matters is that you are not dismissing symptoms that feel more significant than that, and that you have a prescriber you can actually reach when a question comes up. If you would like to talk through your situation before or during treatment, the team at our clinical team reviews consultations personally, every working day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.